Second-line FOLFOX chemotherapy for advanced biliary tract cancer

Tiffany Foo, Ganessan Kichenadasse, Amitesh Roy, Christos S. Karapetis

Research output: Contribution to journalLetterpeer-review


The ABC-06 trial is an important, prospective, randomised phase 3 clinical trial that examined the role of second-line chemotherapy in advanced biliary tract cancers.1 Angela Lamarca and colleagues randomly assigned 162 patients to active symptom control (ASC) and FOLFOX chemotherapy (folinic acid, fluorouracil, and oxaliplatin) or ASC alone. Although the study met its endpoint, the improvement in overall survival was modest....
Original languageEnglish
Pages (from-to)e286
Number of pages1
JournalThe Lancet Oncology
Issue number7
Publication statusPublished - Jul 2021


  • FOLFOX chemotherapy
  • biliary tract cancer
  • intrahepatic cholangiocarcinomas


Dive into the research topics of 'Second-line FOLFOX chemotherapy for advanced biliary tract cancer'. Together they form a unique fingerprint.

Cite this